One Year Later: How Brensocatib Has Changed Bronchiectasis Care

On August 12, 2025, the United States Food and Drug Administration approved Insmed’s brensocatib (Brinsupri), marking the first disease-modifying therapy for non–cystic fibrosis bronchiectasis.¹ The approval, based on the phase 3 ASPEN trial enrolling more than 1700 patients, showed that both the 10-mg and 25-mg doses of brensocatib—an oral, reversible inhibitor of dipeptidyl peptidase-1 that dampens neutrophil-driven airway inflammation—reduced annualized exacerbation rates by 20% compared with placebo, with the higher dose also slowing lung function decline over 12 months.² One year later, HCPLive spoke with 2 pulmonologists who have been prescribing the therapy since its approval about what has changed in day-to-day management of a disease that, until recently, had no targeted treatment options at all.